Our Summer 2024 process progress
HydRegen’s industrial biotechnology platforms deliver sustainable, safe and cost-efficient chemical processes. Partnerships with major chemicals companies have validated these technologies as ‘slot in’ replacements to precious metal catalysts, in existing chemical manufacturing infrastructure, providing a route to fast-tracking adoption of more sustainable bio-based manufacturing across pharma, specialty and bulk chemical sectors.
What's new, overview
We've spent the summer working on
commercially competitive Bio2Amine processes for nitro-to-amine processes,
showcasing our tech routinely running in higher TRL reactors, and
demonstrating a 18-fold improvement in enzyme manufacturing increasing our cost-competitivity across the chemicals sector!
🖥 Product
As we work to increase joint-development projects and licenses for commercial manufacturing, we have taken matters into our own hands. Having previously identified 38 processes of significant interest, we are now ready to showcase the top 16 processes, operating under industrially relevant conditions.
For each of these, we expect a manufacturer to achieve:
3 X CO2e saving,
40 % cost saving,
mitigation of cost and regulation in using precious metal-catalyst, and
provide considerably safer operation
all in existing chemical infrastructure.
Check out our new look technology page to see all the technical notes and process booklets!
🏆 Achievements
In collaboration with experts at enzyme manufacture, we have unlocked an 18-fold improvement over the last few months, representing more than 1000's x improvement since our academic days!
What does this mean?
This makes us 18x more competitive in our current processes, and unlocks more opportunities for us to compete on price for lower value chemicals.
What's next?
We aren't stopping there, our next steps are to further improve the enzyme manufacturing process whilst also showcasing further savings in removing down stream processing steps and increasing productivity. This puts us on the path for being price competitive right across the chemicals sector by 2026.
📢 Shout Outs
Over the summer, we bought in a Uniclave, a higher TRL batch reactor that better mimics pilot scale hydrogenation reactions.
This allows us to:
optimise handling, and engineering for implementing our technologies
continue to intensify and scale up our processes
prepare chemical samples at g-kg scale
de-risk tech transfer to customer pilot plants
We look forward to showcasing early results very soon!
🎙️ Announcements
We are delighted to be in the Start up Market at CPhI Milan in October. Find out more here: About HydRegen Limited. (cphi-online.com)
📈 KPIs
By combining the benefits of milder biological conditions within intensified chemical infrastructure, we unlock at least 3xCO2e and 40% cost savings to our customers. We are now looking to raise £5-8m, focusing on delivering our first product (Bio2Amine) to a first 38 processes, with an end-market of £80bn and opportunity to HydRegen of £500m revenue over 10 years, before ramping our follow-on products into additional markets.